Cybin Aktie

Cybin für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A40NJY / ISIN: CA23256X4075

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
10.02.2026 14:23:16

Helus Pharma Names Michael Cola CEO

(RTTNews) - Helus Pharma (HELP), a clinical stage pharmaceutical company, Tuesday announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.

Cola has more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals and was most recently, the CEO of Avalo Therapeutics.

"With highly differentiated HLP003 clinical data already in hand and a robust pipeline of novel compounds in development, Helus is uniquely positioned to advance a new paradigm in the treatment of serious mental health disorders. I'm excited to work alongside the Board and the Helus team to build on this foundation and translate scientific progress into lasting patient and shareholder impact.", commented Michael Cola.

In pre-market activity, HELP shares were trading at $6.35, up 0.47% on the Nasdaq.

Analysen zu Cybin Inc Registered Shs

mehr Analysen
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Cybin Inc Registered Shs 5,60 -1,75% Cybin Inc Registered Shs